merek dagang untuk preparat amphotericin B cholesteryl complex.
|Trade names||Fungizone, Mysteclin-F|
|I.V. (slow infusion only) topical|
|ATC code||A01AB04 (WHO) A07AA07 (WHO), G01AA03 (WHO), J02AA01 (WHO)|
|Biological half-life||initial phase : 24 hours,
second phase : approx. 15 days
|Excretion||40% found in urine after single cumulated over several days
biliar excretion also important
|Chemical and physical data|
|3D model (Jmol)||Interactive image|
|Melting point||170 °C (338 °F)|
Common side effects include a reaction of fever, shaking chills, headaches and low blood pressure soon after it is infused, as well as kidney and electrolyte problems. Allergic symptoms including anaphylaxis may occur.
It is of the polyene class. It is a subgroup of the macrolide antibiotics, and exhibits similar structural elements. Currently, the drug is available in many forms. Either "conventionally" complexed with sodium deoxycholate (ABD), as a cholesteryl sulfate complex (ABCD), as a lipid complex (ABLC), and as a liposomal formulation (LAMB). The latter formulations have been developed to improve tolerability and decrease toxicity, but may show considerably different pharmacokinetic characteristics compared to conventional amphotericin B.
It was originally made from Streptomyces nodosus in 1955. Its name originates from the chemical's amphoteric properties. It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system.